Media coverage about Eyegate Pharmaceuticals (NASDAQ:EYEG) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eyegate Pharmaceuticals earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 45.8436354695017 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news stories that may have effected Accern’s scoring:
- Eyegate Pharmaceuticals, Inc. (EYEG) is at $1.21 per share and Civitas Solutions, Inc. (CIVI) is listed at $18.90 – Stocks Gallery (stocksgallery.com)
- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Traded Over Its 50 Day Average – First News 24 (firstnewspaper24.com)
- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) Trading Volume Significantly Lower – First News 24 (firstnewspaper24.com)
- Uveitis Treatment Market By Indication, Cause, Condition, and Drug – Global Industry Insights, Trends, Outlook, and … – Medgadget (blog) (medgadget.com)
- Head-To-Head Analysis: SCYNEXIS (SCYX) vs. Eyegate Pharmaceuticals (EYEG) (americanbankingnews.com)
Shares of Eyegate Pharmaceuticals (NASDAQ EYEG) traded up 0.83% during midday trading on Friday, hitting $1.22. The company had a trading volume of 61,829 shares. The firm’s 50-day moving average is $1.18 and its 200-day moving average is $1.18. The firm’s market capitalization is $20.99 million. Eyegate Pharmaceuticals has a 12-month low of $0.96 and a 12-month high of $3.90.
Separately, HC Wainwright set a $6.00 target price on Eyegate Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 8th.
TRADEMARK VIOLATION WARNING: “Eyegate Pharmaceuticals (EYEG) Receiving Somewhat Positive News Coverage, Analysis Finds” was published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://transcriptdaily.com/2017/10/08/eyegate-pharmaceuticals-eyeg-receiving-somewhat-positive-news-coverage-analysis-finds.html.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.